Noteworthy:
"For decades, work in the field has focused on targeting one component of the immune system the T cells which were always seen as the smoking gun of the disease because they attack nerve fibers in the brain, causing the lesions and ultimately the symptoms of multiple sclerosis. Ocrelizumab, in contrast, targets a molecule called CD20 found on the surface of B cells, a separate component of the immune system."